Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib vs sorafenib in unresectable hepatocellular carcinoma (China cohort of REFLECT)
CTR20131648Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lenvatinib in hepatocellular carcinoma (HCC), sponsored by Eisai Co., Ltd.. Started Aug 2014; status: completed.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20131648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131648.